* If you want to update the article please login/register
Mild cognitive impairment is a marker of Alzheimer's disease pathology in Alzheimer's. Because there are no early signs or conventional diagnostic methods, cognitive impairment patients often have a delayed diagnosis. MCI patients and healthy controls were shown to differe protein expression in exosomes between MCI patients and healthy controls by Mass spectrometry and tandem mass tag approach-based non-targeted proteomics, and these differing proteins were validated using immunoblot and enzyme-linked immunosorbent assays. Correlation of cognitive results with the serum exosomal protein level was established. According to a normal control group, people with MCI had a higher serum exosome concentration and a smaller exosome diameter. Using mass spectrometry analysis, we discovered 69 exosomal proteins that were differentially expressed between MCI patients and healthy controls. MCI patients had an elevated incidence of Thirty-nine exosomal proteins relative to those in control patients. The exosomal protein signature from MCI patients reflected the cell adhesion molecule class.
Source link: https://europepmc.org/article/MED/36018182
Background Cognitive inactivity is increasingly recognized as a significant comorbidity of diabetes mellitus. Objectives of this research were to determine the prevalence and predictors of cognitive decline in people with type 2 diabetes mellitus. Methods The study, by the Sheikh Khalifa Zayed Hospital in Casablanca, Morocco, included patients with type 2 diabetes mellitus aged between 40 and 75 years and with a course of diabetes that is greater than five years. Conclusion It's important to recognize the cognitive decline of diabetic patients with diabetes as one of the most significant complications of the disease due to its effects on their growth and compliance of these patients.
Source link: https://europepmc.org/article/MED/PMC9506426
BACKGROUND BIOLOGICS: Mild cognitive impairment is a heterogeneous disease with significant individual variability in clinical outcomes attributed to patient demographics, genetics, brain structure characteristics, blood biomarkers, and comorbidities. Multiple disorders including hypertension are well-known risk factors for Alzheimer's disease, according to multi-modality data-driven studies to identify MCI subtypes; however, disease comorbidities have not been included as a modality; however, disease comorbidities have not been identified as a factor in Alzheimer's disease. The aim of this research was to investigate MCI heterogeneity in the context of AD-related comorbidities, as well as other AD-relevant features and biomarkers. We discovered that comorbidity-driven MCI subtypes differed from those identified without comorbidity information. Participants in the four comorbidity-driven MCI subtypes had significant differences in the proportions of participants who recovered to normal function, remained stable, or converted to AD. Conclusions based on our findings Our report shows that AD comorbidities should be considered alongside other important AD-related characteristics in order to better understand MCI heterogeneity.
Source link: https://europepmc.org/article/MED/36166485
Objective The aim of this paper was to determine the efficacy and potential of a multi-domain amnestic Mild Cognitive Impairment program. Results Our research showed that the neuropsychological outcomes of the TG group after the telerehabilitation intervention improved on a statistically significant level in terms of delayed and working memory, conflict naming, verbal fluency, and global cognition. The earliest comparison between the TG and CG showed a significant effect of the telerehabilitation scheme on memory and language, as well as global cognition results. Specifically, the positive results of the telerehabilitation intervention on episodic memory provide us with optimism and evidence that these types of programs may be used with similar success using face-to-face approaches.
Source link: https://europepmc.org/article/MED/36156732
Current studies are also uncertain regarding the relationship between amyloid positivity and WMH burden and dementia among people with mild cognitive impairment. Methods This report investigated whether WMH burdens differ in both amyloid-negative and amyloid-positive people with MCI who are stable or progress to dementia. In the study with 5054 follow-up time points over a maximum period of 13 years, an average of 5. 7 follow-up timepoints per participant was included. All groups experienced steeper changes in WMH burden over time, with A00df+ progressors seeing the most change in comparison to A00df+ stagnation, which was the most notable change. Conclusion These results show that WMH progression is a contributing factor in dementia change in both amyloid-positive and negative people with MCI.
Source link: https://europepmc.org/article/PPR/PPR549475
Background to measure brain function, cognitive age-related decline has been attributed to dementia development and gait. This study was conducted to see if spatiotemporal gait variables could be used to distinguish between the three cognitive status groups. Using a two-way ANCOVA, effects of cognitive status and walking task were analyzed. Operating Characteristics was used to distinguish between three groups of gait variables. Conclusions Between MCI and dementia and cognitively healthy groups There were significant effects of cognitive stability during both single and dual-task walking in several variables across the MCI and dementia, as well as between dementia and cognitively healthy groups, but no difference was found between the MCI and dementia groups, though no difference was seen between the MCI and cognitively healthy groups. Conclusions Spatiotemporal gait variables demonstrated discriminative capability between dementia and cognitively intact groups in both single and dual tasks. This means that gait could potentially be used as a clinical differentiation indicator for people with cognitive impairments.
Source link: https://europepmc.org/article/MED/36151524
In our latest clinical trial, the Glycyrrhizin and boswellic acids combination has been shown to have very positive results against COVID-19. However, the research is limited due to the small sample size, and, therefore, the aim of this article is to thoroughly review new studies on the efficacy of GR and BAs in preventing COVID-19 disease in patients with mild to moderate infections and in preventing post-COVID-19 cognitive impairment, which is the most common symptom after recovery from Covid-19 disease recovery. GR n and BAs also had high antiviral activity and could be used as a therapeutic agent for COVID-19 and as a shield against SARS-CoV-2. Only seven well-designed clinical trials examining the effectiveness of GR, BAs, or their combinations in the treatment of COVID-19 have been published as of July 2022. Although no research has been done into the treatment of cognitive impairment after COVID-19's publication, so far, several preclinical and clinical trials have shown the potential role of GR and BAs in the prevention and treatment of cognitive impairment by reducing the activity of many hormones that promote inflammation signaling pathways. In conclusion, our study's findings showed that the use of GR and BAs to treat SARS-CoV-2 and its variations, as well as prevention post-COVID cognitive impairment. However, it warrants further investigation with a larger randomized sample size to ensure that the studies have sufficient evidence of benefits against COVID-19 and post-COVID-19 signs and symptoms.
Source link: https://europepmc.org/article/MED/36136251
Background The cognitive impairment gradually brings changes to the marriage between older married couples. This research sought to investigate the personal perspectives of couple dyadic couples on the essential characteristics of a 'good dyadic relationship,' in the context of mild cognitive impairment, in order to determine whether there are any similarities and disparities in their experiences of their relationship and well-being. Methods Q-methodology was used to reveal the results of a 'good dyadic relationship' among couples with one having MCI. On a 7-point Q-sort response grid, the participating couples were divided in two rooms and independently assessed 18 relationship traits from least to most important. The quality of the marriage and closeness with the partner were noted with a significant degree by couples with discrepant views. Both perspectives contribute to this research's theoretical investigation of the dyadic relationship between couples with one having MCI.
Source link: https://europepmc.org/article/MED/36131229
Caspase-2 is a member of the caspase family with both apoptotic and non-apoptotic characteristics, and has been shown to mediate synaptic deficits in models of several neurologic disorders, including Alzheimer's disease, Huntington's disease, and Lewy Body dementia. Capase-2 protein levels in these conditions have been elevated in previous studies, leading to our conclusion that elevated caspase-2 protein levels are owing to increased transcription of caspase-2 mRNA. There are two popular isoforms of caspase-2 mRNA, caspase-2L, and caspase-2S. We tested our hypothesis by testing the serum of these mRNA isoforms normalized to RPL13 mRNA, a reference gene that showed no disease-associated changes. AD's Caspase-2S mRNA showed no trend for a non-significant decline. The mRNA expression remained unchanged between disease groups and controls, with the exception of u03b2III-tubulin mRNA expression remaining unchanged between disease groups and controls. Presynaptic dysfunction leads to cognitive deficits in neurodegeneration, according to a reduction of SNAP25 mRNA expression.
Source link: https://europepmc.org/article/MED/36129947
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions